Moderna Confirms 40 Million COVID-19 Vaccine Dose Supply Agreement with the Government of the Republic of Korea
01 January 2021 - 01:14AM
Business Wire
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today confirmed the
Company has entered into a supply agreement with the government of
the Republic of Korea to provide 40 million doses of the Moderna
COVID-19 Vaccine to support the government’s aim of providing
vaccines to the public as soon as possible. Under the terms of the
proposed agreement, deliveries would begin in May 2021. The Moderna
COVID-19 Vaccine is not currently approved for use in South Korea,
and the Company will work with regulators to pursue the necessary
approvals prior to distribution.
“We thank the Republic of Korea for partnering with us to bring
the Moderna COVID-19 Vaccine to South Korea. The government has
moved very swiftly to get this done in the face of the pandemic. We
believe this supply agreement is an important step towards building
a long-lasting future collaboration between Moderna and the
Republic of Korea,” said Stéphane Bancel, Chief Executive Officer
of Moderna. “We look forward to continuing discussions with
government officials and to building a stronger scientific and
clinical presence of Moderna in South Korea.”
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. The company’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing Moderna the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases, cardiovascular diseases, and
autoimmune and inflammatory diseases, independently and with
strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca PLC
and Merck & Co., Inc., as well as the Defense Advanced Research
Projects Agency (DARPA), an agency of the U.S. Department of
Defense, and BARDA. Moderna has been named a top biopharmaceutical
employer by Science for the past six years. To learn more, visit
www.modernatx.com.
Authorized Use
The Moderna COVID-19 Vaccine has not been approved or licensed
by U.S. Food and Drug Administration (FDA), but FDA has authorized
the vaccine for emergency use in individuals 18 years of age and
older.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding: the Company’s development of
a vaccine against the novel coronavirus, and the potential
provision of the Moderna COVID-19 Vaccine to the government of
South Korea. In some cases, forward-looking statements can be
identified by terminology such as “will,” “may,” “should,” “could”,
“expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,”
“estimates,” “predicts,” “potential,” “continue,” or the negative
of these terms or other comparable terminology, although not all
forward-looking statements contain these words. The forward-looking
statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties, and other factors, many of which are beyond
Moderna’s control and which could cause actual results to differ
materially from those expressed or implied by these forward-looking
statements. These risks, uncertainties, and other factors include,
among others: the fact that there has never been a commercial
product utilizing mRNA technology approved for use; the fact that
the rapid response technology in use by Moderna is still being
developed and implemented; the safety, tolerability and efficacy
profile of the Moderna COVID-19 Vaccine observed to date may change
adversely in ongoing analyses of trial data or subsequent to
commercialization; despite having ongoing interactions with the FDA
or other regulatory agencies, the FDA or such other regulatory
agencies may not agree with the Company’s regulatory approval
strategies, components of our filings, such as clinical trial
designs, conduct and methodologies, or the sufficiency of data
submitted; Moderna may encounter delays in meeting manufacturing or
supply timelines or disruptions in its distribution plans for the
Moderna COVID-19 Vaccine; whether and when any biologics license
applications and/or emergency use authorization applications may be
filed and ultimately approved by regulatory authorities; potential
adverse impacts due to the global COVID-19 pandemic such as delays
in regulatory review, manufacturing and clinical trials, supply
chain interruptions, adverse effects on healthcare systems and
disruption of the global economy; and those other risks and
uncertainties described under the heading “Risk Factors” in
Moderna’s most recent Quarterly Report on Form 10-Q filed with the
U.S. Securities and Exchange Commission (SEC) and in subsequent
filings made by Moderna with the SEC, which are available on the
SEC’s website at www.sec.gov. Except as required by law, Moderna
disclaims any intention or responsibility for updating or revising
any forward-looking statements contained in this press release in
the event of new information, future developments or otherwise.
These forward-looking statements are based on Moderna’s current
expectations and speak only as of the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201231005153/en/
Moderna Media: Colleen Hussey Director, Corporate
Communications 617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Senior Vice President & Head
of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2023 to Mar 2024